Wednesday
Pharma Webinars
Oct. 28th
1
11:00 am – 12:15 pm ET
The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive.
Category: Chronic Diseases

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Douglas Schlichting, RN, PhD
Development Director
Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19
Eli Lilly and Company


David Platt, MD
Vice President, Medical Unit Head
Cardiovascular, Renal & Metabolism Medical Unit
Novartis Pharmaceuticals Corporation


Dr. Sandi See Tai
VP, Medicine Team Lead for Amyloid, Rare Neuro & Cardiac
Pfizer Global Product Development
Pfizer Inc.


Sailaja Bhaskar, BPharm, MS, PhD, MBA
Executive Director, Clinical Operations Planning
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P.


Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs
Eli Lilly and Company

2
12:30 pm – 1:45 pm ET
What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation?
Category: Solid Tumor Cancers

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Sam Spigelman, MD
Senior Global Medical Affairs Leader
Janssen Research & Development, LLC


Sabine Brookman-May, MD, PhD
Executive Medical Director, Late Development, Solid Tumor
Janssen Research & Development, LLC


Ted W. Johnson, PhD
Research Fellow
Medicinal Chemistry, Pfizer Oncology
Pfizer Inc.

3
2:00 pm – 3:00 pm ET
Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia?
Category: Hematologic cancers and other rare diseases

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Ramon V. Tiu, MD
Executive Medical Director, Astellas Pharma Global Development
Global Medical Leader, Gilteritinib Program
Astellas Pharma Inc.


Dr. Michael G. Kauffman, MD, PhD
Chief Executive Officer
Co-Founder
Karyopharm Therapeutics Inc.

4
3:00 pm – 4:00 pm ET
Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall?
Category: Infectious diseases and reproductive health

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING

Mark Sullivan
Founder and Managing Director
Medicines Development for Global Health


Amanda Paschke, MD, MSCE
Executive Director
Global Clinical Development
Merck & Co., Inc.
